Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccines.

Lisa Danzig1

  • 1Chiron Vaccines, Clinical Research and Medical Affairs, Emeryville, CA 94608-2916, USA. lisa_danzig@chiron.com

The Pediatric Infectious Disease Journal
|December 15, 2004
PubMed
Summary

New meningococcal vaccines offer improved protection for infants and children. Conjugate vaccines targeting serogroups A, C, Y, and W135 are advancing, while novel approaches are explored for serogroup B.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular and Serologic Investigation of the 2021 COVID-19 Case Surge Among Vaccine Recipients in Mongolia.

JAMA network open·2022
Same author

A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste.

medRxiv : the preprint server for health sciences·2022
Same author

PaxVax CVD 103-HgR single-dose live oral cholera vaccine.

Expert review of vaccines·2017
Same author

Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain).

Transfusion·2014
Same author

Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions.

Vaccine·2009
Same author

Immune response to conjugated meningococcal C vaccine in pediatric oncology patients.

Pediatric blood & cancer·2007

Area of Science:

  • Bacteriology and Immunology
  • Vaccine Development and Efficacy

Background:

  • Neisseria meningitidis is a Gram-negative bacterium with five major pathogenic serogroups: A, B, C, Y, and W135.
  • Early meningococcal vaccines (1960s) used purified capsular polysaccharides but lacked efficacy in infants and young children.
  • Development shifted to capsular polysaccharide-protein conjugate vaccines for improved immunogenicity in younger populations.

Purpose of the Study:

  • To review the development of second-generation capsular polysaccharide glycoconjugate vaccines.
  • To discuss strategies for creating a broadly protective serogroup B vaccine.
  • To explore novel approaches for meningococcal disease prevention.

Main Methods:

  • Review of second-generation glycoconjugate vaccine development.
  • Evaluation of outer membrane vesicle vaccines for serogroup B.
  • Identification of conserved antigens for broad protection against Neisseria meningitidis.

Main Results:

  • Monovalent serogroup C conjugate vaccines have successfully reduced meningococcal disease burden in the UK and Canada.
  • Tetravalent (A/C/W/Y) conjugate vaccines are nearing late-stage development.
  • Serogroup B polysaccharide-based vaccines have faced challenges; genome sequencing enabled 'reverse vaccinology' for new antigen discovery.

Conclusions:

  • Conjugate vaccines have significantly improved meningococcal disease control, particularly for serogroup C.
  • Advancements in vaccine technology are crucial for addressing remaining serogroups, especially serogroup B.
  • Reverse vaccinology offers a promising new avenue for developing effective serogroup B vaccines.

Related Experiment Videos